Golidocitinib: all 33 studies that test it
Page 1 of 1. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingNCT07754890Phase 1/2
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingNCT07753642Phase 2
- Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung DiseaseNot yet recruitingNCT07737249Phase 2
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingNCT07682792Phase 2
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)RecruitingNCT07525466Phase 1/2
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingNCT07493330Phase 1/2
- Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingNCT07414758Phase 3
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingNCT07369739Phase 2/3
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingNCT07339345Phase 2/3
- Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerNot yet recruitingNCT07303881Phase 2
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingNCT07300514Phase 3
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingNCT07297550Phase 1/2
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingNCT07279584Phase 2
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingNCT07234162Phase 3
- Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07209163Phase 1/2
- An Exploratory Study of Golidocitinib in Adult Patients With ITPNot yet recruitingNCT07196163Phase 1/2
- Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCRecruitingNCT07110103Phase 2
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
- Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingNCT07081607Phase 2
- Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
- A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
- A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
- Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
- Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingNCT06630091Phase 2
- Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
- Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
- AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)CompletedNCT06511895Phase 2
- AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)CompletedNCT06511869Phase 2
- A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)CompletedNCT06295432Phase 2
- Drug-drug Interactions Between AZD4205 and Itraconazole/CarbamazepineCompletedNCT05486949Phase 1
- A Study of AZD4205 in Healthy Adult SubjectsCompletedNCT03728023Phase 1
- Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerCompletedNCT03450330Phase 1/2